# US 2017/0304311 A1 · Pharmaceutical Combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0304311 A1
- Document ID: US20170304311A1
- Status: Published application
- Kind: A1
- Application number: 15/646,494
- Filed: 2017-07-11
- Published: 2017-10-26
- Earliest claimed: 2014-01-15
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Samit Hirawat; Cristian Massacesi
- Web page: https://patentgrep.com/patent/US20170304311A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof and (b) a gonadorelin agonist and, optionally, (c) an antiestrogen agent, particularly for use in the treatment or prevention of a cancer; uses of such a combination in the preparation of a medicament for the treatment or prevention of a cancer; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a cancer in a subject comprising administering to said subject a therapeutically effective amount of such a combination.

## Claims

### Claim 1

A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase (PI3K) inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) a gonadorelin agonist, and, optionally, (c) an antiestrogen agent.

### Claim 2 (depends on 1)

A pharmaceutical combination according to claim 1, wherein the gonadorelin agonist is selected from abarelix, goserelin, buserelin, or any pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

A pharmaceutical combination according to claim 2, wherein the gonadorelin agonist is goserelin acetate.

### Claim 4 (depends on 1)

A pharmaceutical combination according to claim 1, wherein the pharmaceutical combination comprises an antiestrogen agent selected from tamoxifen, fulvestrant, raloxifene, raloxifene hydrochloride or any pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

A pharmaceutical combination according to claim 1, wherein the pharmaceutical combination comprises the antiestrogen agent tamoxifen or any pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A pharmaceutical combination according to claim 1, wherein the pharmaceutical combination comprises gonadorelin agonist goserelin acetate and the antiestrogen agent tamoxifen or any pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A pharmaceutical combination according to claim 1, for simultaneous, separate or sequential use in the treatment of a cancer.

### Claim 8

A method for treating a cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of (a) a phosphatidylinositol-3-kinase (PI3K) inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) a gonadorelin agonist, and, optionally, (c) an antiestrogen agent.

### Claim 9 (depends on 8)

A method according to claim 8, wherein pharmaceutical combination comprises (a) a phosphatidylinositol-3-kinase (PI3K) inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, (b) goserelin or any pharmaceutically acceptable salt thereof and (c) tamoxifen or any pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the cancer is selected from a benign or malignant tumor of the breast, lung, bronchus, prostate, pancreas, colon, rectum, thyroid, liver and intrahepatic bile duct, hepatocellular, gastric, gastrointestine, glioma/glioblastoma, endometrial, melanoma, kidney and renal pelvis, adrenal gland, bladder, uterus, cervix, ovary, esophagus, brain, head and neck, small intestine, multiple myeloma, leukemia, non-Hodgkin lymphoma, villous colon adenoma, a neoplasia, a neoplasia of epithelial character and combinations thereof.

### Claim 11 (depends on 8)

A method according to claim 8, wherein the cancer is hormone-receptor positive breast cancer.

### Claim 12

A combined preparation comprising: (a) one or more dosage units of a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, and (b) one or more dosage units of a gonadorelin agonist for use in the treatment of a cancer.

### Claim 13 (depends on 12)

A combined preparation according to claim 12, further comprising one or more dosage units of an antiestrogen agent.

### Claim 14 (depends on 1)

A commercial package comprising as active ingredients the pharmaceutical combination according to claim 1 and instructions for simultaneous, separate or sequential administration of said pharmaceutical combination to a patient in need thereof for use in the treatment of a cancer.

### Claim 15 (depends on 1)

A commercial package comprising as active ingredient a phosphatidylinositol-3-kinase (PI3K) inhibitor according to claim 1 and instructions for simultaneous, separate or sequential administration of said active ingredient with a gonadorelin agonist to a patient in need thereof for use in the treatment of a cancer.
